Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1197 of 6351
-
New COVID-19 vaccine shows promise in small trial
Vaccine CompletedThis study will determine the immunogenicity of Spikogen in vaccine naïve individuals. Spikogen will be administered as two doses 1 month apart with a third booster dose either 1 or 3 months after the second dose. This study will provide key data on SARS-CoV-2 antibody responses.…
Phase 3 • Sponsor: Vaxine Pty Ltd • Aim: Vaccine
Last updated Jun 26, 2026 17:42 UTC
-
New cancer drug AOH1996 enters first human tests
Disease control Recruiting nowThis phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could a simple exercise program speed healing of diabetic foot ulcers?
Disease control CompletedDiabetic foot ulcers are a common complication of diabetes mellitus and are associated with delayed wound healing, impaired quality of life, and an increased risk of lower extremity amputation. Although regular exercise is recommended for people with diabetes, evidence regarding …
Sponsor: Harran University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Asthma rescue without needles: nasal spray could replace shots
Disease control CompletedARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
Phase 2 • Sponsor: ARS Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug combo aims to stop liver cancer in its tracks
Disease control Recruiting nowThe investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival…
Phase 2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New lung drug aims to slow scarring in IPF patients
Disease control OngoingThis study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
Phase 2 • Sponsor: PureTech • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Engineered immune cells take aim at childhood liver cancers
Disease control Recruiting nowOpen-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HC…
Phase 1/2 • Sponsor: Eureka Therapeutics Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Weekly shot may help 'double diabetes' patients control blood sugar
Disease control Recruiting nowBetween 16% and 22% of type 1 diabetic patients present a clinical and biological profile of insulin resistance favored by a family history of type 2 diabetes or metabolic syndrome. They constitute a group of patients with "double diabetes" since they have both true type 1 diabet…
Phase 3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope for Hard-to-Treat lung condition: satralizumab trial targets inflammation
Disease control CompletedExamine the efficacy of satralizumab in patients with pulmonary arterial hypertension (PAH) with immune-responsive phenotype serum interleukin-6 (IL-6) ≥ 2.73 pg/mL who have an inadequate response to existing drugs.
Phase 2 • Sponsor: International University of Health and Welfare • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug shows promise for lung cancer brain metastases
Disease control CompletedThis study is a single-arm, open-label, prospective phase II trial. The aim of this phase II study is to evaluate the efficacy and safety of Furmonertinib in patients with EGFR mutation (including 19del or 21L858R or T790M) in advanced NSCLC with brain metastases.
Phase 2 • Sponsor: Peking Union Medical College • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New eye drug shows promise in battle against blinding disease
Disease control CompletedA non-inferiority design was used to conduct a randomized, double-blind, parallel-controlled multi-center study. A total of 488 subjects with neovascular (wet) age-related macular degeneration (w-AMD) were planned to be enrolled. Qualified subjects were divided into experimental …
Phase 3 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New osteoporosis drug shows promise in Head-to-Head trial
Disease control CompletedThe Study will be conducted to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis. The primary goal for the study is 1. To evaluate the efficacy of ENZ215 when c…
Phase 3 • Sponsor: Enzene Biosciences Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
AI may solve tricky liver diagnosis puzzle
Knowledge-focused CompletedA retrospective, multi-center, non-interventional cohort study has been going to explore whether artificial intelligence can discriminate Drug-induced liver injury and Autoimmune hepatitis. A machine learning-based tool will be developed and validated to help clinicians to diffe…
Sponsor: Beijing Friendship Hospital • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
New pill aims to quiet schizophrenia psychosis in weeks
Symptom relief CompletedThis is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia a…
Phase 2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 26, 2026 18:42 UTC
-
Breast cancer drug tested in everyday patients
Disease control Recruiting nowThis is a prospective, multicenter, open-label, non-comparative, non-interventional, observational study to assess te safety and effectiveness of Piqray in the real-world setting
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a Stepped-Care approach make PTSD therapy more effective?
Symptom relief Recruiting nowThis trial is being completed to develop a stepped-care talk therapy model for patients with PTSD. Specifically, this study is testing whether beginning with one type of therapy is better than beginning with another type of therapy, and whether moving to a different therapy after…
Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Could a phone call help rural americans beat colon cancer?
Prevention CompletedThis study aims to test the effectiveness of a remotely-delivered patient navigation program for increasing colonoscopy completion for colorectal cancer screening, among rural populations. The study will partner with geographically disparate primary care organizations to recruit …
Sponsor: University of Washington • Aim: Prevention
Last updated Jul 17, 2026 00:00 UTC
-
Could a dissolvable scaffold and your own fat replace silicone breast implants?
Disease control CompletedThe clinical trial is testing the use of a novel method to grow new tissue within the breast injecting fat tissue harvested from patient's own fat deposits. A scaffold implant acts as a absorbable frame to support this growth of cells. The scaffold will be absorbed within at leas…
Sponsor: BellaSeno Pty Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New digital PET/CT could spot hidden artery inflammation and prevent blindness
Diagnosis CompletedGiant cell arteritis (GCA) causes inflammation of the arteries and can lead to serious complications such as blindness, necessitating rapid diagnosis and treatment. Although older technology non-digital PET/CT scans are routinely used for the diagnosis of GCA in large arteries, t…
Sponsor: Jewish General Hospital • Aim: Diagnosis
Last updated Jun 26, 2026 13:06 UTC
-
New hope for hepatitis b patients with normal ALT: TMF drug trial underway
Disease control OngoingThis is a multicenter, randomized, open, blank controlled trial ,in order to evaluate the effectiveness and safety of Amibufenamide(TMF) in the treatment of chronic hepatitis B virus infection patients with normal ALT .
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC